Effects of<i>Nigella sativa</i>on outcome of hepatitis C in Egypt

Barakat, Eman; Wakeel, Lamia Mohamed El; Hagag, Radwa Samir

doi:10.3748/wjg.v19.i16.2529

Cited by 134 publications

(109 citation statements)

References 46 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…In another study, administration of N. sativa oil (16.88 mg/kg/day for 3 months) in patients with HCV decreased the viral load and improved oxidative stress, clinical condition, and glycemic control. N. sativa administration was safe in all patients, and only one patient reported epigastric pain and hypoglycemia (Barakat et al, 2013).…”

Section: Antimicrobial Effectsmentioning

confidence: 99%

Preclinical and clinical effects of Nigella sativa and its constituent, thymoquinone: A review

Gholamnezhad

Havakhah

Boskabady

2016

Journal of Ethnopharmacology

234

150

View full text Add to dashboard Cite

Section: Antimicrobial Effectsmentioning

confidence: 99%

Preclinical and clinical effects of Nigella sativa and its constituent, thymoquinone: A review

Gholamnezhad

Havakhah

Boskabady

2016

Journal of Ethnopharmacology

234

150

View full text Add to dashboard Cite

“…The treatment significantly reduced the viral load and augmented α-fetoprotein and other liver function parameters among the cases. Another study by Barakat et al (2013) investigated the beneficial effect of Nigella sativa oil administration to patients with cirrhosis and chronic liver disease. A significant reduction of viral load and total cure (seronegative status) among 50% and 16.67% of the cases was observed.…”

Section: Discussionmentioning

confidence: 99%

Selective Inhibition of Hepatitis C Virus Replication by Alpha-Zam, a Nigella Sativa Seed Formulation

Oyero¹,

Toyama²,

Mitsuhiro³

et al. 2016

Afr J Tradit Complement Altern Med

View full text Add to dashboard Cite

Background: Hepatitis C virus (HCV) infection became curable because of the development of direct acting antivirals (DAAs). However, the high cost of DAAs has greatly impeded their potential impact on the treatment of HCV infection. As a result, hepatitis C will continue to cause substantial morbidity, and mortality among chronically infected individuals in low and middle income countries. Thus, urgent need exists for developing cheaper drugs available to hepatitis C patients in these countries. Materials and Methods: Alpha-zam, an indigenous herbal formulation from Nigella sativa seed, was examined for its anti-HCV activity and cytotoxicity in genotype 1b HCV replicon cells. The antiviral activity was determined by luciferase expression and viral RNA synthesis, while the cytotoxicity was assessed by viable cell number and glyceraldehyde-3-phosphate dehydrogenase RNA synthesis in the replicon cells. Results: Alpha-zam was found to be a selective inhibitor of HCV replication. The 50% effective dilution and 50% cytotoxic dilution of Alpha-zam were 761-and < 100-fold, respectively, in the subgenomic replicon cells LucNeo#2. Its selective inhibition of HCV was also confirmed by HCV RNA levels in LucNeo#2 and in the full-genome HCV replicon cells NNC#2 using real-time reverse transcriptase polymerase chain reaction. Furthermore, the anti-HCV activity of Alpha-zam was not due to the induction of interferon. Conclusion: Alpha-zam selectively inhibits HCV replication and therefore has potential for a novel antiviral agent against HCV infection.

show abstract

“…The Egyptian Demographic Health Survey (EDHS), a crosssectional survey conducted in 2008, estimated the HCV prevalence in the 15-to 59-year-old age group to be 14.7 % [2]. Accordingly, Egypt has the highest HCV prevalence in the world and the highest prevalence of HCV-4 (67 %), which reflects a national-level epidemic [3][4][5]. HCV infection and its complications are among the leading public-health challenges in Egypt [6,7].…”

Section: Introductionmentioning

confidence: 99%

Single-nucleotide polymorphism of Toll-like receptor 4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients

et al. 2015

View full text Add to dashboard Cite

Egypt has the highest prevalence of hepatitis C virus (HCV) in the world. It has been suggested that not only the virus but also the interaction between the virus and the host immune system is important in determining the course of the infection and the response to interferon (IFN)-based therapy. While the adaptive immune system plays a critical role in HCV infection, the innate immune system has only been recognized recently. Toll-like receptors (TLRs) form the cornerstone of the innate immune response. Interleukin-10 (IL-10) is one of the upstream regulators of TLR4. A possible interplay between TLR4 and IL-10 has been suggested. The present study aimed to investigate the role of single-nucleotide polymorphisms (SNPs) in TLR4 and IL-10-1082 and the expression levels of these proteins in predicting the response to treatment in chronic HCV patients. A total of 83 chronic HCV-infected Egyptian patients treated with peg-IFN-a2b-ribavirin combination therapy and 40 healthy subjects were included in this study. SNPs in the TLR4 rs2149356 and IL-10-1082 genes and their serum levels were assessed. Within the responders group, T/T and A/A genotypes were the significantly most frequent genotypes of TLR4 and IL-10-1082, respectively. Moreover, a higher frequency of T/T and A/A was found to be associated with lower serum TLR4 and IL-10 levels in our responder patients. In addition, subjects with the T/T genotype in the healthy control group had a lower serum TLR4 level than those with other genotypes. We conclude that the SNPs

show abstract

Effects ofNigella sativaon outcome of hepatitis C in Egypt

Abstract: N. sativa administration in patients with HCV was tolerable, safe, decreased viral load, and improved oxidative stress, clinical condition and glycemic control in diabetic patients.

Cited by 134 publications

References 46 publications

Preclinical and clinical effects of Nigella sativa and its constituent, thymoquinone: A review

Preclinical and clinical effects of Nigella sativa and its constituent, thymoquinone: A review

Selective Inhibition of Hepatitis C Virus Replication by Alpha-Zam, a Nigella Sativa Seed Formulation

Single-nucleotide polymorphism of Toll-like receptor 4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients

Contact Info

Product

Resources

About